Intranasal MEAI Shows Strong Nasal Retention in Preclinical Study
CMND is trading near its 52-week low of $1.74 (2.9% above the low) on light trading volume (0.1× avg).
Summary
Clearmind reported positive ex vivo mucoadhesion results for its intranasal MEAI formulation, showing markedly improved nasal residence time versus a standard solution. The study used rabbit nasal mucosa and demonstrated consistent retention advantage over 30 minutes, supporting the company's intranasal delivery platform. This is a preclinical step toward a more effective dosing method for its lead psychedelic-based compound targeting alcohol use disorder. The news adds to a series of recent clinical and IP milestones, including completed Phase I/IIa dosing and new patents. While early-stage, the data validates the formulation approach and could differentiate MEAI in a competitive neuroplastogen space.
At the time of this announcement, CMND was trading at $1.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $1.74 to $524.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.